⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dimethylamine SCHEMBL9702906 | 0.95 | MMP1 (0.43) | — | |
| Diethylamine SCHEMBL9700337 | 0.91 | MCL1 (0.42) | — | |
| SCHEMBL6858080 | 0.85 | MMP1 (0.52) | — | |
| SCHEMBL584355 | 0.84 | EPHX1 (0.54) | — | |
| SCHEMBL7876750 | 0.82 | EPHX1 (0.60) | — | |
| SCHEMBL2175844 | 0.82 | KDM5B (0.47) | — | |
| SCHEMBL377344 | 0.80 | MMP1 (0.40) | — | |
| SCHEMBL11419656 | 0.80 | EPHX1 (0.64) | — | |
| SCHEMBL10916993 | 0.80 | EPHX1 (0.64) | — | |
| SCHEMBL8293272 | 0.80 | EPHX1 (0.64) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115449900-A | Texturing treating agent, preparation method thereof and method for texturing monocrystalline silicon wafer | 浙江奥首材料科技有限公司 | 2022-12-09 | — | — | CN | claimed |
| EP-2168957-B1 | Alkyl-substituted tetrahydropyranes as aromatic materials | SYMRISE AG (DE) | 2012-02-15 | — | — | EP | claimed |
| EP-0350260-A2 | New oxamic acid compounds and pharmaceutical composition for use in improvement of damaged cerebral functions of brain | MEIJI SEIKA KAISHA LTD. (JP) | 1990-01-10 | — | — | EP | claimed |
| CN-118356515-A | FAP-targeted conjugate with radionuclide and application thereof | 广州医科大学附属第一医院（广州呼吸中心） | 2024-07-19 | — | — | CN | disclosed |
| US-20230321135-A1 | TARGETING OF LACTATE DEHYDROGENASE C, METHODS OF PREPARING SAME, AND METHODS OF USING SAME IN COMBINATION WITH ANTI-CANCER TREATMENTS | HAMAD BIN KHALIFA UNIVERSITY (QA) | 2023-10-12 | — | — | US | disclosed |
| WO-2023102523-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCES, INC. (US) | 2023-06-08 | — | — | WO | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| EP-3904357-A1 | SPIRO COMPOUND AND MEDICAL USES THEREOF | The National Institutes of Pharmaceutical R&D Co., Ltd (CN) | 2021-11-03 | — | — | EP | disclosed |
| CN-108552186-A | Use of phenylpyrazoline-3-carboxylates for increasing plant yield | 拜耳知识产权有限责任公司 | 2018-09-21 | — | — | CN | disclosed |
| US-20170239362-A1 | Growth Hormones with Prolonged In-Vivo Efficacy | NOVO NORDISK HEALTHCARE AG (CH) | 2017-08-24 | — | — | US | disclosed |
| US-9695226-B2 | Growth hormones with prolonged in-vivo efficacy | NOVO NORDISK HEALTHCARE AG (CH) | 2017-07-04 | — | — | US | disclosed |
| US-9695226-B2 | Growth hormones with prolonged in-vivo efficacy | NOVO NORDISK HEALTHCARE AG (CH) | 2017-07-04 | — | — | US | disclosed |
| US-20160058879-A1 | Growth Hormone Compound Formulation | NOVO NORDISK HEALTHCARE AG (CH) | 2016-03-03 | — | — | US | disclosed |
| US-9234192-B2 | Conjugated proteins | NOVO NORDISK A/S (DK) | 2016-01-12 | — | — | US | disclosed |
| US-8841249-B2 | Growth hormones with prolonged in-vivo efficacy | NOVO NORDISK A/S (DK) | 2014-09-23 | — | — | US | disclosed |
| US-8779109-B2 | Growth hormones with prolonged in-vivo efficacy | NOVO NORDISK HEALTH CARE AG (CH) | 2014-07-15 | — | — | US | disclosed |
| US-20140107324-A1 | Growth Hormones with Prolonged In-Vivo Efficacy | NOVO NORDISK HEALTH CARE AG (CH) | 2014-04-17 | — | — | US | disclosed |
| US-20130004524-A1 | Conjugated Proteins | NOVO NORDISK A/S (DK) | 2013-01-03 | — | — | US | disclosed |
| US-20120309944-A1 | Growth Hormones With Prolonged In-Vivo Efficacy | NOVO NORDISK HEALTH CARE AG (CH) | 2012-12-06 | — | — | US | disclosed |
| US-20120172303-A1 | Growth Hormones with Prolonged In-Vivo Efficacy | NOVO NORDISK HEALTH CARE AG (CH) | 2012-07-05 | — | — | US | disclosed |